Tata Capital Healthcare Fund II (TCHF II), the healthcare focused private equity fund of Tata Capital Ltd., has invested an amount of $ 20 million in Orbicular Pharmaceutical Technologies for an undisclosed equity stake. Orbicular, a Hyderabad-based specialty pharmaceutical company, excelling in developing complex generics for global pharmaceutical markets, will utilise the capital for accelerating the development of product pipeline.

The specialty generics industry (market size $ 60+ billion) is rapidly expanding, driven by increasing demand for cost-effective alternatives to complex and high-cost branded medications. Orbicular has developed a robust pipeline of niche products in the specialty generics space positioning them as an ideal partner for global generic players targeting regulated markets.

Speaking on the partnership, Visalakshi Chandramouli, Managing Partner, Tata Capital Healthcare Fund said, “Under the able leadership of Dr M.S. Mohan, Orbicular has developed a strong product pipeline for the regulated markets. We are proud to support the dynamic team at Orbicular and be a part of their growth story. This investment reinforces our fund’s core philosophy of identifying the big shifts in the industry and being a “capital plus” partner to our companies.